Cingulate to Submit New Drug Application Leveraging Precision Timed Release Technology
TL;DR
Investors in Cingulate (NASDAQ: CING) may gain an edge with the company's innovative Precision Timed Release™ (PTR™) technology.
Cingulate's PTR™ technology allows a single pill to contain multiple doses of a drug, providing relief for people with chronic conditions.
Cingulate's drug technology aims to make life easier for those with chronic conditions, reducing the burden of taking multiple pills.
Cingulate's Precision Timed Release™ (PTR™) technology is a game-changer in drug delivery, offering hope for those with chronic conditions.
Found this article helpful?
Share it with your network and spread the knowledge!
Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), recently appeared on Benzinga’s All Access to discuss the company's latest advancements. Cingulate is a biotechnology firm focused on developing drugs for various underserved conditions. Central to their innovation is the Precision Timed Release™ (PTR™) technology, which enables a single pill to deliver multiple doses of a drug. This approach aims to alleviate the pill burden experienced by individuals managing chronic conditions.
Cingulate has announced plans to submit a New Drug Application (NDA) within the next year. The company's proprietary PTR™ technology could redefine treatment protocols for chronic diseases, potentially improving patient compliance and outcomes. This advancement is particularly relevant as the healthcare industry seeks solutions that simplify medication regimens and enhance the quality of life for patients.
The interview with Dr. Childress and Shane Schaffer provides deeper insights into the company's vision and the potential impact of their forthcoming NDA submission. The full interview is available for viewing on YouTube.
Featured photo by Thought Catalog on Unsplash.
Curated from News Direct
